Overview of Strongid

Property	Description
Active Ingredient	Pyrantel (as Pyrantel Pamoate)
Form	Oral Paste, Liquid Suspension, Tablets
Pharmacological Class	Anthelmintic (Antinematodal Agent)
General Purpose	Removal and control of internal parasites
Origin	Synthetic chemical compound

Strongid is the recognized trade name for a medication whose active component is the synthetic compound Pyrantel, which is primarily classified as an Anthelmintic drug used to clear parasitic roundworms from the digestive system. Its foundational purpose is the targeted removal and control of internal parasites—specifically nematodes—making it an essential agent in both human and veterinary healthcare.

Identity, Classification, and Origin of Strongid

Pyrantel is identified chemically as a Tetrahydropyrimidine derivative, which establishes its core synthetic origin. Its high-level classification is as an Antinematodal Agent. The drug operates by acting as a depolarizing neuromuscular-blocking agent on the parasite. This physiological action causes the susceptible nematodes to undergo immediate spastic paralysis, which is the mechanism that prevents them from anchoring to the intestinal wall. Strongid is positioned as a reliable solution often used for routine deworming.

Composition and Available Pharmaceutical Forms

The active substance is most commonly formulated as the Pyrantel Pamoate crystalline salt (also referred to as Pyrantel Embonate). This particular salt form is critical because its minimal water solubility ensures the medication is largely nonabsorbed from the host’s digestive tract, concentrating the drug's activity locally within the lumen of the intestine. The medication is designed for oral administration and is available as a single-ingredient product in various physical dosage form(s), including a flavored Liquid Suspension, a palatable Oral Paste, and Tablets.

General Therapeutic Function: The Role of Pyrantel

The primary therapeutic function of Pyrantel is to achieve swift and decisive parasitic clearance. As a luminal drug, its function is focused entirely on the parasites themselves, utilizing spastic paralysis to ensure the immobilized worms are rendered passive. This loss of motility enables the efficient expulsion of the parasitic burden from the body via normal peristalsis and defecation, fulfilling the core therapeutic requirement of this Anthelmintic agent.

Regulatory References

What side effects are possible with Strongid?

Possible Side Effects and Safety Information

The safety profile of Pyrantel Pamoate (Strongid) is derived from its regulatory classification and observed clinical use, focusing primarily on effects within the gastrointestinal system and other organ classes. The medication is minimally absorbed from the digestive tract, which concentrates its activity locally.

Officially Documented Adverse Reactions

The adverse reactions listed in regulatory documents are organized primarily by affected body system. These effects may sometimes occur during treatment and are generally concentrated in the gastrointestinal system and nervous system.

System-Organ Class	Documented Adverse Reactions
Gastrointestinal	Abdominal cramps, Nausea, Vomiting, Diarrhea
Nervous System	Headache, Dizziness
Hepatobiliary System	Transient elevation of liver enzymes (SGOT/AST)
Skin	Skin rash

Serious adverse reactions are not explicitly listed in the core human medicine labels; however, the possibility of transient increases in liver enzymes (aspartate aminotransferase) is noted in some regulatory texts.

Population-Specific Safety Constraints

The official labeling includes specific restrictions and cautions concerning certain populations. Safety constraints include using the medicine with caution in individuals with pre-existing liver disease. Furthermore, regulatory documentation advises constraints on use for pregnant individuals and children under two years old unless under the direct guidance of a physician.

Safety restrictions also prohibit simultaneous use with piperazine compounds due to opposing physiological actions. The medication is also constrained against use in individuals with known hypersensitivity to any of its components.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Strongid (Pyrantel Pamoate) overdose reflects the drug's limited systemic absorption. Consequently, overdose is primarily associated with clinical manifestations related to the gastrointestinal system and the central nervous system, which are typically classified as mild and transient. No severe or life-threatening systemic outcomes are explicitly documented in regulatory labeling.

Clinical Signs and Manifestations	Regulatory Mandate
Gastrointestinal System	When to Seek Urgent Help
Abdominal cramps, nausea, vomiting, and diarrhea.	Contact a Poison Control Center immediately.
Central Nervous System	Management Strategy
Headache, dizziness, and fatigue.	Symptomatic and supportive treatment; no specific antidote is known.

The low toxicity profile established by regulatory authorities indicates that a significant overdose typically leads only to these mild effects. However, official labeling mandates immediate medical contact if an accidental overdose is suspected or confirmed. This instruction aligns with the overall regulatory constraint that the management of overdose is defined as providing symptomatic and supportive treatment to address the documented mild effects. The explicit instruction is to seek professional assistance and contact a Poison Control Center right away.

Therapeutic Uses of Strongid

What Strongid Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms linked to conditions involving parasitic infections. The medication is considered relevant for easing the discomfort associated with these conditions. A brief listing of indications includes symptoms associated with infections such as pinworm and roundworm.

Easing Acute Discomfort and Managing Symptom Intensity

The medication is applied across domains where additional symptomatic support is needed and is relevant in contexts marked by increased discomfort related to irritative states. It helps address symptom clusters that may become intense or disruptive, such as local irritation and related gastrointestinal discomfort. The medication contributes to easing the overall symptom burden.

“Applied in clinical settings that involve acute or unstable symptom patterns, the medication is often used during phases when symptoms become more noticeable.”

Providing Supportive Relief in Challenging Symptomatic Phases

The medication is considered relevant in conditions characterized by periods of heightened symptoms and is applied during phases where symptoms may temporarily interfere with daily functioning. By providing supportive relief, the treatment contributes to improved comfort during periods of heightened symptoms, which may help patients cope more steadily with symptom fluctuations. It supports patients during difficult episodes by easing distress in settings where short-term symptomatic assistance is needed.

Quick Fact: Relief for Infection-Related Discomfort

Regulatory References

Pyrantel: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Strongid (Pyrantel Pamoate)

Strongid is subject to specific regulatory eligibility rules that define who can and cannot use the medicine, based on government-approved labeling.

Populations Contraindicated or Restricted

Classification	Population Entity	Official Statement Basis
Contraindicated	Patients with known hypersensitivity to pyrantel pamoate or any component.	Absolute Exclusion
Restricted Use	Children under 2 years of age or weighing less than 25 pounds (11 kg).	Use requires physician direction.
Conditional Use	Patients who are pregnant or have liver disease.	Do not use unless directed by a physician.

Age-Group Eligibility

Standard unsupervised use is allowed for adults and children 2 years of age and over who meet the minimum weight threshold. The prescribing information indicates no specific data comparing use in older adults to other age groups. The FDA classifies use in pregnancy as Category C, and official labeling restricts use during pregnancy without medical consultation. While there is no specific data on excretion into human milk, pyrantel is considered compatible with breastfeeding by the WHO due to poor systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Strongid (pyrantel pamoate) is based on official government regulatory documentation, primarily focusing on pharmacodynamic conflict and concentration changes.

Contraindicated and Restricted Combinations

Interacting Substance	Interaction Type	Regulatory Restriction
Piperazine	Pharmacodynamic Antagonism	Contraindicated: Should not be co-administered due to opposing effects on neuromuscular function.
Organophosphorus Compounds	Potential for Toxicity	Restricted: Concurrent use is advised against in some regulatory texts.

Population and Administration Notes

Official labeling contains specific notes regarding interaction constraints:

Liver Disease: Patients with pre-existing liver disease (hepatic impairment) should only use pyrantel pamoate under professional guidance.
Administration: The product is typically administered without regard to meals; there are no widely documented requirements for separating the dose from food or juice to avoid interaction.

Mechanism of Action

Strongid (Pyrantel) operates by targeting the specific motor control system within susceptible parasitic worms, resulting in the parasite's loss of physiological motility and function.

Targeting Parasitic Nicotinic Acetylcholine Receptors

Pyrantel acts as a persistent agonist at specialized nicotinic acetylcholine receptors (nAChRs) found only on the worm's muscle cells . This molecular engagement initiates the mechanistic cascade by forcing the receptor into a state of continuous activation.

Mechanism of Spastic Paralysis

The sustained receptor activation causes an unrelenting electrical signal (depolarization) in the parasite's muscle membrane, leading to an overload. This results in a depolarizing neuromuscular block that locks the worm's entire musculature into a rigid, non-functional state known as spastic paralysis.

Physiological Consequence and Functional Limitation

The resulting paralysis causes the worm to lose its capacity to anchor itself to the intestinal wall or move actively. The inert parasites are then subject to passive expulsion from the host via normal peristalsis. The mechanism is functionally restricted to the intestinal lumen because the drug is minimally absorbed by the host, and it is ineffective against worms that lack the specific target receptor.

Dosage and Administration Information

The administration of Strongid (Pyrantel Pamoate) is defined by established patterns concerning dose calculation, route of ingestion, and treatment schedule. The route of administration for all available dosage forms—including the oral suspension and tablets—is solely oral.

Dosing Principle and Frequency

The standard regimen is determined by the patient's weight, with the dose calculated at 11 milligrams of the active pyrantel base per kilogram of body weight. The total amount administered in any single dose must not exceed 1 gram (1000 mg).

The frequency pattern is dependent on the infection. For roundworm, the medication is typically administered as a single dose. For pinworm, the process involves repeating the single dose two weeks after the initial administration to address the parasite's lifecycle. A longer course is established for hookworm infections, which are treated with the 11 mg/kg dose taken once daily for three consecutive days.

Administration Context and Preparation

Regarding practical administration, the medicine may be taken with or without food, as its efficacy is not dependent on mealtimes. No prior or concurrent use of a laxative is required. If the liquid suspension is used, it must be shaken well before the dose is measured using an accurate device to ensure correct ingestion. These instructions define a standardized approach to utilizing the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Strongid

Evidence for Pinworm Infection (Enterobiasis)

Research exploring Pyrantel Pamoate in the context of pinworm infection primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews. These studies evaluated the compound in populations including school-aged children and adults, with many trials focusing on family or community settings. The studies monitored the endpoints of parasite presence or absence. Specifically, they measured the Parasitological Cure Rate and the Egg Reduction Rate, which monitors the decrease in the overall parasitic burden. Research highlights changes measured during the study period, often describing patterns related to short-term parasite clearance observed in the studied populations.

Evidence for Roundworm Infection (Ascariasis)

Research examining Pyrantel Pamoate in the context of roundworm infection, due to Ascaris lumbricoides, was evaluated in a number of RCTs and comparative field trials. Study populations largely included school-aged children and adults residing in endemic areas. The main outcomes studied monitored the physiological strain or stress caused by the parasite. Data show patterns related to parasite presence or absence, and findings describe a consistent profile when measuring the short-term change in the number of parasites. Much of this research was derived from settings involved in mass drug administration for population control.

What is Still Uncertain in the Research Record

Long-term effects are not fully established, and follow-up durations were limited across the evidence base, typically restricted to a few weeks post-treatment. The evidence provides limited insight into the prevention of recurrence. Data for certain groups remain insufficient, specifically, research provides limited insight into long-term outcomes for adults and older populations. Furthermore, evidence remains limited for the observed characteristics of repeated or maintenance doses over extended periods, as most research focuses on single-dose or short-course applications for acute measured change.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Strongid (FAQ)

Q: What is Strongid used for in pets versus humans?

A: Regulatory documents indicate that Pyrantel Pamoate is used in both human and veterinary healthcare. In humans, it is indicated for the treatment of pinworm infection, according to official labeling. In the veterinary context, it is approved for the removal and control of hookworms and roundworms (ascarids) in various animal species.

Q: Is Strongid a type of antibiotic?

A: No, Strongid is not an antibiotic. According to regulatory agencies like the NIH, it is officially classified as an Anthelmintic, which is a type of medication used to treat or prevent infections caused by parasitic worms.

Q: Can I give my puppy/kitten Strongid?

A: Specific veterinary products containing Pyrantel Pamoate are not recommended for very young animals, such as puppies under two to three weeks of age or kittens under eight weeks of age, or those weighing under specific thresholds. If considering use for a young animal, consulting with a veterinarian is advised according to official guidance.

Q: Is Strongid safe for pregnant or nursing animals?

A: Regulatory documents advise that caution should be exercised when using this medication in pregnant or nursing animals. In these circumstances, official information advises that a veterinarian be consulted to discuss the specific risks and benefits.

Q: Why do some people use Strongid for pinworms?

A: The medication is officially indicated for the treatment of pinworm infection in humans. It is selected for this purpose because of its targeted mechanism of action against the parasite in the intestinal tract.

Q: Does Strongid treat tapeworms as well as roundworms?

A: According to official product information, Pyrantel Pamoate is effective against hookworms and roundworms (nematodes). However, when used as a single agent, it is not effective against tapeworms (cestodes).

Q: Is there a liquid or chewable form of Strongid?

A: Yes, Pyrantel Pamoate is generally available in an oral suspension (liquid) and tablet forms for administration. Some combination products available for veterinary use may be formulated as chewable tablets.

Q: What are the signs of a Strongid overdose?

A: While specific signs of overdose are not consistently detailed in patient-facing labels, regulatory documents strongly advise that in the event of accidental ingestion or suspected overdose, professional medical help or a poison control center (or veterinarian for pets) should be contacted immediately.

Q: How quickly does Strongid start working after taking it?

A: Clinical pharmacology data shows that the concentration of the drug reaches its peak in the bloodstream typically within one to three hours after ingestion. The medication's primary action is localized to the gut.

Q: What kind of parasites does Strongid treat?

A: In humans, the medication is indicated for pinworms. In animals, it is indicated for the treatment of common intestinal parasites, including roundworms and hookworms.

Q: Can Strongid cause drowsiness or lethargy in my pet?

A: Yes, official veterinary labels list potential side effects in animals that include lethargy, which is a lack of energy or sluggishness. Other documented side effects may include vomiting or diarrhea.

Q: What are the most common side effects of Strongid in animals?

A: The most frequently reported side effects in animals, as noted in veterinary regulatory documents, are temporary issues such as vomiting, diarrhea, loss of appetite, and lethargy.

Q: Do I need a prescription from a vet to get Strongid?

A: For human pinworm treatment, the active ingredient Pyrantel Pamoate is often available over-the-counter (OTC) without a prescription in the US. For veterinary use, the classification may vary by specific product and location, and a prescription may be required.

Q: Why is Strongid sometimes given in two doses spaced apart?

A: For the treatment of certain infections, such as pinworm, official instructions specify repeating the dose after a period of time, commonly two weeks. This frequency is typically recommended because the initial dose targets adult worms, while the second dose helps address any eggs that may hatch later.

Q: Can Strongid affect a pet's liver or kidneys?

A: Pyrantel is partially metabolized in the liver. While use is cautioned in patients with pre-existing liver disease, kidney-related constraints are not prominently noted in official information.

Q: Is Strongid considered safe for senior or older pets?

A: Official veterinary labeling suggests that the medication should be used with caution in animals that are old, weak, or frail. A veterinarian should be consulted before use in senior pets.

Q: How long does Strongid stay in the pet's system?

A: The drug is poorly absorbed into the body, with a large percentage eliminated directly in the feces. While it is cleared from the systemic circulation relatively quickly, its primary action is localized to the intestinal tract.

Q: Are there documented cases of allergic reactions to Strongid?

A: Severe allergic reactions (hypersensitivity) are listed in official documents as a potential, though uncommon, side effect. Known hypersensitivity to any component of the drug is an absolute contraindication for use.

Q: What should I do if my pet vomits after taking Strongid?

A: Official veterinary guidance advises contacting a veterinarian for further instructions if a pet vomits shortly after the medication has been administered.

Q: Does the efficacy of Strongid decrease over time?

A: Official information and veterinary resources note that parasite resistance to anthelmintic drugs is an ongoing issue. Resistance may lead to reduced drug effectiveness over time in a given population of parasites.

Q: Is Strongid effective against whipworms?

A: Official product information for Pyrantel Pamoate states that as a single agent, it is not effective against whipworms.

Q: Can Strongid be used in livestock or only small animals?

A: Veterinary labels indicate the drug is approved for use in large animals, such as horses and ponies, in addition to small animals like dogs and cats.

Q: What is the maximum number of times Strongid can be given in a year?

A: The drug is typically given as a single dose; repetition or frequency should only occur as directed by a healthcare provider. The recommended frequency is based on the specific infection being treated and the official retreatment schedule.

Q: Are there generics of Strongid available?

A: Yes, the active ingredient Pyrantel Pamoate is widely available as a generic medication under various brand names, in addition to the original Strongid trade name.

Q: Can Strongid be used to treat other types of infestations, like fleas?

A: No. Official documents classify this drug as an Anthelmintic, meaning it is specifically intended for treating intestinal parasites (worms) and is not indicated for treating external infestations like fleas or ticks.

Q: Does Strongid require any special preparation before administration?

A: According to official instructions, no special preparation is required before use. The drug can typically be taken with or without food, and a laxative is not required before, during, or after treatment.

Q: Are there restrictions on activity after giving Strongid?

A: Because dizziness is a possible, though uncommon, side effect, caution is advised before engaging in activities like driving or operating machinery until the effects of the drug are known.

Q: Is it common to see dead worms in the feces after Strongid?

A: Official information indicates the drug paralyzes the worms, which are then naturally passed from the body. It is possible for worms or pieces of worms to be visible in the stool after treatment.

Q: Does Strongid have a strong taste that pets dislike?

A: Official veterinary documents note that certain animals, particularly cats, may exhibit increased drooling (salivation) as a potential side effect, which can be a reaction to the taste of the medication.

Q: What ingredients are in Strongid besides the active medication?

A: In addition to the active ingredient Pyrantel Pamoate, regulatory labels (such as those for the oral suspension) list inactive ingredients. These commonly include purified water, sucrose, glycerin, flavorings, and various preservatives.

Q: Can Strongid cause behavioral changes in animals?

A: Official veterinary regulatory documents list lethargy (lack of energy or activity) as a possible adverse reaction in animals.

How should Strongid be stored and disposed of?

Storage and Disposal of Strongid (Pyrantel Pamoate)

The storage and disposal of Strongid must adhere strictly to the conditions defined in official regulatory labeling.

Requirement	Official Regulatory Statement
Storage Temperature	Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Environmental Constraints	Product must be protected from direct sunlight and kept from freezing (Do Not Freeze).
Container & Handling	Store in the original, tightly closed container. The liquid suspension must be shaken thoroughly before every use; diluted product must not be stored.
Child Safety	Mandatory instruction: Keep out of the sight and reach of children.
Disposal	Disposal of unused or expired product must be done in accordance with local authority requirements. Avoid discharge into drains or water courses.

Official regulatory documents define the storage profile by mandating controlled room temperature and protection from light and freezing. The product must remain in the original container to maintain stability. Disposal is governed by local authority requirements for pharmaceutical waste.

Strongid